Alnylam Gets $20M From Takeda
Luke Timmerman10/7/08
Alnylam Pharmaceuticals said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceutical as part of the collaboration formed between the companies in May. The money is for transferring documents, materials, and know-how to Takeda for developing RNA interference-based drugs. Alnylam (NASDAQ: ALNY) has already received a $100 million upfront payment from Takeda for closing the deal.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
